This article was originally published in The Rose Sheet
Executive Summary"Good progress" has been made on the integration and rejuvenation of the acne treatment brand, which contributed over $114.5 mil. (£1=$1.46) in sales worldwide in its first full year, Boots says in its fiscal 2002 financial review May 30. Operating profits for the brand rose by over 13% to $97.9 mil. for the year ended March 31 and the total investment in Clearasil reached $165.8 mil., retailer adds. In the U.S., retail sales for Clearasil were up 1% to $34.4 mil. in the 52 weeks ended April 21, according to Information Resources, Inc. data for food, drug and mass outlets, excluding Wal-Mart...
You may also be interested in...
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.
Device Week, 12 December 2019 – Global Insulin Pump Market Will Face Fierce Rivalry Among Major Players In 2020
In this edition of Device Week, Medtech Insight's deputy editor Reed Miller chats with managing editor Marion Webb about her latest in-depth Market Intel story, the first part of a two-part series focusing on the competitive landscape of the global insulin pump market.
COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its CEO tells Scrip.